CG Oncology bags $105 million to finance bladder cancer pipeline

Privately-held USA-based CG Oncology, previously known as Cold Genesys, has announced the closing of an oversubscribed $105 million crossover financing round.

The company said that the proceeds will support the continued advancement of clinical programs in bladder cancer towards US Food and Drug Administration (FDA) approval including BOND-003, a fully enrolled, single-arm, Phase III, monotherapy study for cretostimogene grenadenorepvec as a potential treatment for high-risk non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).

CG Oncology has a licensing agreement with Japanese drugmaker Kissei Pharmaceutical (TYO: 4547) for its oncolytic immunotherapy drug, previously code-named CG0070, for Japan, South Korea, Taiwan and other Asian countries with the exception of China.